The Lancet Neurology in conversation with Podcast Por The Lancet Group capa

The Lancet Neurology in conversation with

The Lancet Neurology in conversation with

De: The Lancet Group
Ouça grátis

OFERTA POR TEMPO LIMITADO: Apenas R$ 0,99/mês nos primeiros 3 meses

Renova automaticamente por R$ 19,90/mês após 3 meses

Sobre este título

Editors at The Lancet Neurology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.

A monthly audio companion to the journal, this podcast covers a broad range of topics, from sleep habits to amyloid biomarkers in Alzheimer’s, the diagnosis and classification of optic neuritis to treatment of Creutzfeldt-Jakob disease, and more.

© 2026 The Lancet Group
Ciências Doença Física Higiene e Vida Saudável
Episódios
  • Niklas Mattsson-Carlgren on the use of biomarkers in the diagnosis and stratification of Alzheimer's disease
    Mar 18 2026

    In this episode, Laura Hart and Elena Becker-Barroso speak with Niklas Mattsson-Carlgren (Lund University) about the use of blood biomarkers in the diagnosis and stratification of Alzheimer's disease. They discuss two particular plasma biomarkers—p-tau217 and eMTBR-tau243—including what they measure and how a proposed practical two-step approach that uses p-tau217 as an initial screen in a neurology clinic, and then eMTBR-tau243 for those who test positive, could support diagnostic decisions.

    Click here to read the full article:

    https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00029-3/fulltext

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Exibir mais Exibir menos
    15 minutos
  • Cristina Tassorelli on migraine prevention
    Feb 18 2026

    In this episode, Senior Editor Morgane Boillot speaks with Professor Cristina Tassorelli (University of Pavia, Italy) about recent advances in migraine prevention.
    Together with colleagues, Tassorelli has authored a Review in the journal examining the major developments in migraine-specific pharmacological treatments over the past decade, with a particular focus on therapies targeting the CGRP pathway.

    In this conversation, they explore what these advances mean for people living with migraine and for clinicians, discuss promising emerging targets for prevention and the future of biomarkers, and consider whether it is time to redefine the goals of migraine prevention with greater ambition.

    Click here to read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00477-6/fulltext

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Exibir mais Exibir menos
    23 minutos
  • Inga Zerr and Simon Mead on advances in prion diseases
    Jan 21 2026

    Our Editor-in-Chief, Elena Becker-Barroso, speaks with Inga Zerr (DZNE, Göttingen, Germany) and Simon Mead (UCL London, UK) about the latest advances in prion diseases.

    In collaboration with other experts, Zerr and Mead have authored a Series in the journal that covers the genetic factors behind these diseases, and new diagnostic and prognostic biomarkers.

    Click here to read the full articles:

    https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00451-X/fulltext
    https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00406-5/fulltext

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Exibir mais Exibir menos
    29 minutos
Ainda não há avaliações